USP1092溶出度试验的开发和验证(中英文对照版).pptxVIP

（1092）溶出度试验的开发和验证【中英文对照版】 INTRODUCTION 前言 Purpose 目的 The Dissolution Procedure: Developmentand Validation 1092 provides a comprehensive approach covering items to considerfor developing and validating dissolution procedures and the accompanyinganalytical procedures. It addresses the use of automation throughout the testand provides guidance and criteria for validation. It also addresses thetreatment of the data generated and the interpretation of acceptance criteriafor immediate- and modified-release solid oral dosage forms. 溶出实验:开发和验证（1092）指导原则提供了在溶出度方法开发和验证过程中 以及采用相应分析方法时需要考虑的因素。本指导原则贯穿溶出度实验的全部过 程，并对方法提供了指导和验证标准。同时它还涉及对普通制剂和缓释制剂所生 成的数据和接受标准进行说明。 Scope 范围 Chapter 1092 addresses the development andvalidation of dissolution procedures, with a focus on solid oral dosage forms.Many of the concepts presented, however, may be applicable to other dosageforms and routes of administration. General recommendations;are given with theunderstanding that modifications of the apparatus and procedures as given in USPgeneral chapters need to be justified. 1092章节讨论了溶出度实验的开发和验证，重点是口服固体制剂。所提 出的许多概念也可能适用于其他剂型和给药途径。关于设备和方法的修改部分在 USP 通则中给出了合理的说明。 The organization of 1092 follows the sequence of actions often performed inthe development and validation of a dissolution test. The sections appear inthe following sequence. 在进行溶解度实验的开发和验证时，常遵循指导原则1092，具体内容如 下： 1. PRELIMINARY ASSESSMENT (FOR EARLY STAGES OF PRODUCTDEVELOPMENT/DISSOLUTION METHOD DEVELOPMENT) 前期评估（对产品开发以及溶出度方法开发的前期研究评估） Performing Filter Compatibility 滤膜相容性研究 Determining Solubility and Stability of DrugSubstance in Various Media 原料药在不同溶出介质中溶解度测定和稳定性研究 Choosing a Medium and Volume 溶出介质和体积选择 Choosing an Apparatus 1.4 溶出设备选择（桨法和篮法以及其他方法） 2. METHOD DEVELOPMENT;3;4;5;6;7;8;9;10;11;12;13;14;concentration of 0.5 M in combination with SDS. This can beavoided by using the sodium phosphate salt when preparing media with SDS. 反离子或pH 值可能会影响表面活性剂溶液的溶解性或稳定性。例如，当含 有 SDS 的磷酸盐缓冲液中钾盐浓度为 0.5mol/L 时，就形成了沉淀析出，但是 使用磷酸钠制备含有 SDS 的介质时，可以避免这种现象发